CA2509526A1 - Methodes et reactifs destines au traitement de maladies et de troubles associes a des niveaux accrus de cytokines pro-inflammatoires - Google Patents

Methodes et reactifs destines au traitement de maladies et de troubles associes a des niveaux accrus de cytokines pro-inflammatoires Download PDF

Info

Publication number
CA2509526A1
CA2509526A1 CA002509526A CA2509526A CA2509526A1 CA 2509526 A1 CA2509526 A1 CA 2509526A1 CA 002509526 A CA002509526 A CA 002509526A CA 2509526 A CA2509526 A CA 2509526A CA 2509526 A1 CA2509526 A1 CA 2509526A1
Authority
CA
Canada
Prior art keywords
ssri
composition
patient
peg
corticosteroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002509526A
Other languages
English (en)
Inventor
Palaniyandi Manivasakam
Brendan Smith
Jason Fong
Benjamin A. Auspitz
M. James Nichols
Curtis Keith
Grant R. Zimmermann
Bradley B. Brasher
Noah Sachs
Todd W. Chappell
Edward Roydon Jost-Price
Daniel Grau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zalicus Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32074779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2509526(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2509526A1 publication Critical patent/CA2509526A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne une méthode de traitement d'un patient diagnostiqué, ou susceptible de développer un trouble immuno-inflammatoire par administration à ce patient d'un SSRI (inhibiteur sélectif de recaptage de la sérotonine) ou d'un analogue, ou d'un métabolite de ce produit, et, éventuellement, d'un corticostéroïde ou d'un autre composé. Elle concerne aussi une composition pharmaceutique contenant un SSRI, ou un analogue, ou un métabolite de ce produit et un corticostéroïde ou un autre composé, destinée au traitement ou à la prévention d'un trouble immuno-inflammatoire.
CA002509526A 2002-09-24 2003-09-24 Methodes et reactifs destines au traitement de maladies et de troubles associes a des niveaux accrus de cytokines pro-inflammatoires Abandoned CA2509526A1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US41304002P 2002-09-24 2002-09-24
US60/413,040 2002-09-24
US41726102P 2002-10-09 2002-10-09
US60/417,261 2002-10-09
US42752602P 2002-11-19 2002-11-19
US42742402P 2002-11-19 2002-11-19
US60/427,526 2002-11-19
US60/427,424 2002-11-19
US46475303P 2003-04-23 2003-04-23
US60/464,753 2003-04-23
PCT/US2003/030156 WO2004030618A2 (fr) 2002-09-24 2003-09-24 Methodes et reactifs destines au traitement de maladies et de troubles associes a des niveaux accrus de cytokines pro-inflammatoires

Publications (1)

Publication Number Publication Date
CA2509526A1 true CA2509526A1 (fr) 2004-04-15

Family

ID=32074779

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002509526A Abandoned CA2509526A1 (fr) 2002-09-24 2003-09-24 Methodes et reactifs destines au traitement de maladies et de troubles associes a des niveaux accrus de cytokines pro-inflammatoires

Country Status (12)

Country Link
EP (1) EP1553955A4 (fr)
JP (1) JP2006503905A (fr)
AR (1) AR041386A1 (fr)
AU (1) AU2003299196A1 (fr)
BR (1) BR0314713A (fr)
CA (1) CA2509526A1 (fr)
HR (1) HRP20050355A2 (fr)
IS (1) IS7811A (fr)
MX (1) MXPA05003152A (fr)
NO (1) NO20051669L (fr)
TW (1) TW200422042A (fr)
WO (1) WO2004030618A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023146426A1 (fr) * 2022-01-28 2023-08-03 Faculdade De Farmácia Da Universidade De Lisboa Fluvoxamine pour le traitement du psoriasis

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1599212A4 (fr) * 2003-02-14 2006-02-08 Combinatorx Inc Polytherapie servant au traitement de troubles immuno-inflammatoires
AU2004275777A1 (en) * 2003-09-24 2005-04-07 Combinatorx, Incorporated Therapeutic regimens for administering drug combinations
JP2007538083A (ja) * 2004-05-17 2007-12-27 コンビナトアールエックス インコーポレーティッド 免疫炎症性障害の治療のための方法および試薬
MX2007006045A (es) * 2004-11-19 2007-06-13 Organon Nv Combinacion farmaceutica que comprende inhibidor selectivo de reabsorcion de serotonina y antagonista del receptor de glucocorticoide para tratamiento de depresion.
AU2011236053B2 (en) * 2004-11-19 2014-06-26 Merck Sharpe & Dohme B.V. Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
AR054249A1 (es) * 2005-04-13 2007-06-13 Astion Dev As Tratamiento de enfermedades del tejido conectivo de la piel
JP4832806B2 (ja) * 2005-06-03 2011-12-07 久光製薬株式会社 経皮投与製剤
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
US20080234345A1 (en) * 2006-09-08 2008-09-25 Gene Logic Inc. Method for reducing or alleviating inflammation in the digestive tract
US20080064709A1 (en) * 2006-09-11 2008-03-13 Duke University Methods and compositions for the treatment of vascular depression
GB0701171D0 (en) * 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof
WO2010098230A1 (fr) * 2009-02-27 2010-09-02 久光製薬株式会社 Préparation transdermique
WO2024074699A1 (fr) * 2022-10-07 2024-04-11 Oculis Operations Sarl Microsuspensions de gouttes oculaires d'inhibiteurs de mtor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122139B2 (ja) * 1991-10-15 2001-01-09 マラーキー，ミッシェル，エフ． 後期段階炎症反応の治療用組成物
GB9603137D0 (en) * 1996-02-15 1996-04-17 Merck Sharp & Dohme Therapeutic agents
WO1998002169A2 (fr) * 1996-07-15 1998-01-22 Alza Corporation Nouvelles preparations pour l'administration de fluoxetine
TR199902615T2 (xx) * 1997-03-18 2000-03-21 Basf Aktiengesellschaft Kortikosteroidlere verilen cevab�n mod�lasyonuna y�nelik metodlar ve kompozisyonlar.
US6281248B1 (en) * 2000-02-16 2001-08-28 Magda Abdel Fattah Ahmed Composition for treating asthma
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023146426A1 (fr) * 2022-01-28 2023-08-03 Faculdade De Farmácia Da Universidade De Lisboa Fluvoxamine pour le traitement du psoriasis

Also Published As

Publication number Publication date
AU2003299196A1 (en) 2004-04-23
TW200422042A (en) 2004-11-01
NO20051669L (no) 2005-06-10
IS7811A (is) 2005-04-19
MXPA05003152A (es) 2006-04-27
WO2004030618A3 (fr) 2005-04-07
HRP20050355A2 (en) 2005-10-31
WO2004030618A2 (fr) 2004-04-15
JP2006503905A (ja) 2006-02-02
AR041386A1 (es) 2005-05-18
BR0314713A (pt) 2005-07-26
EP1553955A4 (fr) 2008-11-05
EP1553955A2 (fr) 2005-07-20

Similar Documents

Publication Publication Date Title
US8080553B2 (en) Methods and reagents for the treatment of immunoinflammatory disorders
US20040224876A1 (en) Combination therapy for the treatment of immunoinflammatory disorders
US20090075951A1 (en) Methods and Reagents for the Treatment of Inflammatory Disorders
WO2005079284A2 (fr) Methodes et reactifs pour le traitement de maladies et de troubles lies a des niveaux accrus de cytokines proinflammatoires
US20100210606A1 (en) Methods and reagents for the treatment of inflammatory disorders
HRP20050355A2 (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20060286177A1 (en) Methods and reagents for the treatment of inflammatory disorders
US20040220153A1 (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
RU2329037C2 (ru) Комбинированная терапия для лечения иммуновоспалительных заболеваний
ZA200502708B (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
MXPA06005457A (es) Metodos y reactivos para el tratamiento de desordenes inmuno-inflamatorios

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead